X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4964) 4964
Publication (482) 482
Newsletter (415) 415
Book Review (39) 39
Book Chapter (25) 25
Magazine Article (14) 14
Conference Proceeding (13) 13
Dissertation (10) 10
Newspaper Article (4) 4
Web Resource (2) 2
Data Set (1) 1
Government Document (1) 1
Reference (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3017) 3017
pyrazinamide (2948) 2948
tuberculosis (2062) 2062
male (1497) 1497
female (1444) 1444
adult (1260) 1260
pyrazinamide - therapeutic use (1259) 1259
index medicus (1204) 1204
antitubercular agents - therapeutic use (1192) 1192
isoniazid - therapeutic use (970) 970
tuberculosis, pulmonary - drug therapy (968) 968
rifampin - therapeutic use (958) 958
middle aged (902) 902
drug therapy, combination (858) 858
mycobacterium tuberculosis - drug effects (804) 804
rifampin (728) 728
isoniazid (710) 710
pyrazinamide - pharmacology (698) 698
pyrazinamide - administration & dosage (681) 681
microbiology (678) 678
tuberculosis - drug therapy (648) 648
infectious diseases (641) 641
pharmacology & pharmacy (631) 631
antitubercular agents - administration & dosage (621) 621
animals (586) 586
rifampin - administration & dosage (583) 583
antitubercular agents - pharmacology (569) 569
isoniazid - administration & dosage (546) 546
ethambutol - therapeutic use (528) 528
adolescent (525) 525
aged (487) 487
mycobacterium-tuberculosis (483) 483
antitubercular agents - adverse effects (456) 456
drug therapy (456) 456
respiratory system (443) 443
drugs (423) 423
rifampicin (420) 420
treatment outcome (415) 415
research (410) 410
mycobacterium tuberculosis (402) 402
pulmonary tuberculosis (402) 402
ethambutol (400) 400
drug resistance (364) 364
pyrazinamide - adverse effects (364) 364
time factors (350) 350
microbial sensitivity tests (343) 343
mycobacterium tuberculosis - isolation & purification (341) 341
antitubercular agents (319) 319
child (310) 310
analysis (279) 279
mice (278) 278
drug resistance, microbial (271) 271
mycobacterium tuberculosis - genetics (271) 271
drug administration schedule (269) 269
ethambutol - administration & dosage (269) 269
streptomycin - therapeutic use (262) 262
immunology (260) 260
chemotherapy (253) 253
rifampin - adverse effects (250) 250
drug resistance in microorganisms (249) 249
pharmacokinetics (241) 241
isoniazid - adverse effects (233) 233
antitubercular agents - pharmacokinetics (224) 224
susceptibility (224) 224
tuberculosis, multidrug-resistant - drug therapy (223) 223
tuberculosis, pulmonary - microbiology (223) 223
medicine, general & internal (218) 218
risk factors (216) 216
mutation (213) 213
isoniazid - pharmacology (200) 200
drug combinations (199) 199
antituberculosis drugs (192) 192
young adult (191) 191
follow-up studies (182) 182
tuberculosis - microbiology (180) 180
child, preschool (176) 176
infection (176) 176
moxifloxacin (175) 175
pyrazinamide - analogs & derivatives (175) 175
streptomycin - administration & dosage (174) 174
health aspects (172) 172
hepatotoxicity (172) 172
resistance (172) 172
rifampin - pharmacology (172) 172
sputum - microbiology (169) 169
streptomycin (169) 169
research article (168) 168
diagnosis (167) 167
rifampin - pharmacokinetics (167) 167
retrospective studies (165) 165
pyrazinamide - pharmacokinetics (163) 163
dosage and administration (159) 159
antibiotics, antitubercular - therapeutic use (155) 155
uric acid - metabolism (154) 154
medicine (152) 152
recurrence (151) 151
uric acid - blood (149) 149
infant (148) 148
therapy (148) 148
pharmacology (146) 146
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4569) 4569
French (174) 174
German (128) 128
Spanish (110) 110
Italian (104) 104
Japanese (100) 100
Russian (80) 80
Polish (47) 47
Chinese (32) 32
Portuguese (24) 24
Korean (15) 15
Turkish (15) 15
Hungarian (13) 13
Dutch (7) 7
Czech (4) 4
Norwegian (3) 3
Romanian (3) 3
Swedish (3) 3
Hebrew (2) 2
Serbian (2) 2
Bulgarian (1) 1
Danish (1) 1
Persian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 6/2009, Volume 48, Issue 12, pp. 1685 - 1694
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 07/2018, Volume 62, Issue 7
Despite progress, the mechanisms of action and resistance of pyrazinamide (PZA) are not well understood. We characterized 109 mutants resistant to pyrazinoic... 
Pyrazinamide | Tuberculosis | Antibiotic resistance | PYRAZINAMIDE RESISTANCE | antibiotic resistance | pyrazinamide | tuberculosis | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | ASPARTATE DECARBOXYLASE PAND | PNCA MUTATIONS
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2014, Volume 58, Issue 2, pp. 782 - 788
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
MYCOBACTERIUM-TUBERCULOSIS | GATIFLOXACIN | SUSCEPTIBILITY TESTS | BACTERICIDAL ACTIVITY | LEVOFLOXACIN | POPULATION PHARMACOKINETICS | TREATMENT OUTCOMES | PULMONARY TUBERCULOSIS | RIFAMPIN | PYRAZINAMIDE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | Sputum - microbiology | Tuberculosis, Pulmonary - microbiology | Amikacin - pharmacokinetics | Humans | Middle Aged | Kanamycin - pharmacokinetics | Levofloxacin - pharmacokinetics | Ofloxacin - therapeutic use | Male | Tuberculosis, Pulmonary - drug therapy | Fluoroquinolones - pharmacokinetics | Mycobacterium tuberculosis - drug effects | Microbial Sensitivity Tests | Tuberculosis, Pulmonary - blood | Tuberculosis, Multidrug-Resistant - microbiology | Amikacin - blood | Levofloxacin - therapeutic use | Adult | Female | Kanamycin - blood | Antitubercular Agents - therapeutic use | Ofloxacin - blood | Ethionamide - therapeutic use | Pyrazinamide - pharmacokinetics | Tanzania | Levofloxacin - blood | Fluoroquinolones - therapeutic use | Kanamycin - therapeutic use | Ofloxacin - pharmacokinetics | Pyrazinamide - blood | Pyrazinamide - therapeutic use | Cycloserine - therapeutic use | Antitubercular Agents - blood | Ethionamide - pharmacokinetics | Amikacin - therapeutic use | Cycloserine - blood | Fluoroquinolones - blood | Antitubercular Agents - pharmacokinetics | Cycloserine - pharmacokinetics | Ethionamide - blood | Adolescent | Tuberculosis, Multidrug-Resistant - blood | Mycobacterium tuberculosis - growth & development | Tuberculosis, Multidrug-Resistant - drug therapy | Clinical Therapeutics
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1577 - 1587
Journal Article
International Journal of Antimicrobial Agents, ISSN 0924-8579, 2005, Volume 26, Issue 4, pp. 298 - 303
Pharmacokinetic and chemotherapeutic studies have been carried out with aerosolised alginate nanoparticles encapsulating isoniazid (INH), rifampicin (RIF) and... 
Antitubercular drugs | Alginate | Tuberculosis | Nebulisation | alginate | DELIVERY-SYSTEM | INFECTIOUS DISEASES | nebulisation | ACID | MURINE TUBERCULOSIS | tuberculosis | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | antitubercular drugs | FORMULATION | Lung - microbiology | Rifampin - pharmacokinetics | Drug Carriers - therapeutic use | Alginates - therapeutic use | Drug Carriers - administration & dosage | Hexuronic Acids - administration & dosage | Male | Spleen - microbiology | Time Factors | Tuberculosis - drug therapy | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Lung - metabolism | Glucuronic Acid - administration & dosage | Rifampin - administration & dosage | Drug Evaluation, Preclinical | Tuberculosis - metabolism | Antitubercular Agents - therapeutic use | Pyrazinamide - administration & dosage | Guinea Pigs | Isoniazid - pharmacokinetics | Liver - metabolism | Pyrazinamide - pharmacokinetics | Glucuronic Acid - therapeutic use | Mycobacterium tuberculosis - isolation & purification | Pyrazinamide - therapeutic use | Inhalation | Isoniazid - administration & dosage | Alginates - administration & dosage | Animals | Antitubercular Agents - pharmacokinetics | Spleen - metabolism | Aerosols | Antitubercular Agents - administration & dosage | Nanostructures - chemistry | Hexuronic Acids - therapeutic use | Drugs | Nanoparticles | Chemotherapy | Drug delivery systems | Drug therapy | Pyrazinamide | Rifampin | Cancer | Vehicles
Journal Article
The Lancet Infectious Diseases, ISSN 1473-3099, 07/2018, Volume 18, Issue 7, pp. 779 - 787
Journal Article
Microbiome, ISSN 2049-2618, 07/2017, Volume 5, Issue 1, pp. 71 - 17
Background: Effective treatment of Mycobacterium tuberculosis (Mtb) infection requires at least 6 months of daily therapy with multiple orally administered... 
16S rRNA | Microbiota | Tuberculosis | Antibiotics | Dysbiosis | BACTERIA | EARLY-LIFE | ANTIBIOTIC USE | ORAL VANCOMYCIN | TUBERCULOSIS INFECTION | HOST | MICROBIOLOGY | GUT MICROBIOTA | IMMUNE-SYSTEM | DISEASE | MICE | Dysbiosis - etiology | Tuberculosis, Pulmonary - microbiology | Antitubercular Agents - adverse effects | Isoniazid - adverse effects | Tuberculosis, Pulmonary - drug therapy | Mycobacterium tuberculosis - drug effects | Rifampin - adverse effects | Porphyromonas - genetics | Clostridiales - genetics | Isoniazid - therapeutic use | Rifampin - therapeutic use | Porphyromonas - isolation & purification | Rifampin - administration & dosage | RNA, Ribosomal, 16S | Antitubercular Agents - therapeutic use | Pyrazinamide - administration & dosage | Pyrazinamide - adverse effects | Intestines - pathology | Gastrointestinal Microbiome - genetics | Pyrazinamide - therapeutic use | Isoniazid - administration & dosage | Animals | Gastrointestinal Microbiome - drug effects | Intestines - microbiology | Antitubercular Agents - administration & dosage | Clostridiales - isolation & purification | Mice | Drug Combinations | Microbiota (Symbiotic organisms) | RNA | Analysis | Pyrazinamide | Health aspects | Rifampin | Community structure | Obesity | Dysbacteriosis | Animal models | rRNA 16S | Oral administration | Infections | Genomes | Metabolism | Drug resistance | Asthma | Studies | Inflammatory bowel disease | Infectious diseases | Intestine | Bacteria | Intestinal microflora | Diabetes | Isoniazid
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 04/2001, Volume 183, Issue 8, pp. 1300 - 1303
The bactericidal activity of orally administered antituberculosis (anti-TB) drugs was determined in a whole blood culture model of intracellular infection in... 
pyrazinamide
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 06/2009, Volume 37, Issue 3-4, pp. 257 - 263
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 1/2017, Volume 73, Issue 1, pp. 65 - 70
Journal Article
Journal Article
Journal Article